The European Medicines Agency has granted small and medium-sized enterprise status to Innocrin Pharmaceuticals, a designation that provides the company with financial incentives to continue developing its prostate cancer therapy seviteronel (VT-464). Seviteronel (VT-464) treats an aggressive form of the disease known as castration-resistant prostate cancer (CRPC). It inhibits CYP17 lyase, an enzyme involved in the production of male hormones known as androgens and female hormones known as estrogens. It also blocks the androgen receptors that attract androgens. Both of seviteronel's roles are important because prostate cancer cannot grow without androgens. A growing body of research, including clinical trials, indicates seviteronel stops the growth of CRPC that is resistant to the standard therapies Zytiga (abiraterone), Xtandi (enzalutamide) or a combination of the two. The U.S. Food and Drug Administration granted fast track designation to seviteronel in December 2015 as a treatment of CRPC. CYP17 lyase inhibitors have also shown potential for treating other cancers driven by androgen receptors, including breast, ovarian, bladder, liver and lung cancers. In addition, there is evidence the inhibitors could be used to treat non-cancerous conditions stemming from excess androgen production, including endometriosis, polycystic ovary syndrome, and congenital adrenal hyperplasia. The financial incentives that Innocrin will receive from its small and medium-sized enterprise designation include a 90 to 100 percent decrease in fees that European regulators levy for scientific advice and facilities inspection.